<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
  • Menu
  • crown-logo-symbol-1-400x551

Find it Quickly

Get Started

Select the option that best describes what you are looking for

  • Services
  • Models
  • Scientific Information

Search Here For Services

Click Here to Start Over

Search Here For Models

Click Here to Start Over

Search Here For Scientific Information

Click Here to Start Over

In Vitro

Boost oncology drug discovery with XenoBase®, featuring the largest cell line selection and exclusive 3D organoid models. Benefit from OrganoidXplore™ and OmniScreen™ for rapid, in-depth analysis.

Learn More

In Vivo

Enhance drug development with our validated in vivo models, in vitro/ex vivo assays, and in silico modeling. Tailored solutions to optimize your candidates.

Learn More


Experience ISO-certified biobanking quality. Access top biospecimens from a global clinical network, annotated by experts for precise research.

Learn More

Biomarkers and Bioanalysis

Leverage our global labs and 150+ scientists for fast, tailored project execution. Benefit from our expertise, cutting-edge tech, and validated workflows for reliable data outcomes.

Learn More

Data Science and Bioinformatics

Harness your data and discover biomarkers with our top bioinformatics expertise. Maximize data value and gain critical insights to accelerate drug discovery and elevate projects.

Learn More


Accelerate innovative cancer treatments with our advanced models and precise drug screening for KRAS mutations, efficiently turning insights into clinical breakthroughs.

Learn More


Advance translational pharmacology with our diverse pre-clinical models, robust assays, and data science-driven biomarker analysis, multi-omics, and spatial biology.

Learn More

Drug Resistance

Our suite integrates preclinical solutions, bioanalytical read-outs, and multi-omics to uncover drug resistance markers and expedite discovery with our unique four-step strategy.

Learn More

Patient Tissue

Enhance treatments with our human tumor and mouse models, including xenografts and organoids, for accurate cancer biology representation.

Learn More


Apply the most appropriate in silico framework to your pharmacology data or historical datasets to elevate your study design and analysis, and to improve your chances of clinical success.

Learn More

Biomarker Analysis

Integrate advanced statistics into your drug development projects to gain significant biological insight into your therapeutic candidate, with our expert team of bioinformaticians.

Learn More


Accelerate your discoveries with our reliable CRISPR solutions. Our global CRISPR licenses cover an integrated drug discovery platform for in vitro and in vivo efficacy studies.

Learn More


Rely on our experienced genomics services to deliver high quality, interpretable results using highly sensitive PCR-based, real-time PCR, and NGS technologies and advanced data analytics.

Learn More

In Vitro High Content Imaging

Gain more insights into tumor growth and disease progression by leveraging our 2D and 3D fluorescence optical imaging.

Learn More

Mass Spectrometry-based Proteomics

Next-generation ion mobility mass spectrometry (MS)-based proteomics services available globally to help meet your study needs.

Learn More

Ex Vivo Patient Tissue

Gain better insight into the phenotypic response of your therapeutic candidate in organoids and ex vivo patient tissue.

Learn More

Spatial Multi-Omics Analysis

Certified CRO services with NanoString GeoMx Digital Spatial Profiling.

Learn More

Biomarker Discovery

De-risk your drug development with early identification of candidate biomarkers and utilize our biomarker discovery services to optimize clinical trial design.

Learn More

DMPK Services

Rapidly evaluate your molecule’s pharmaceutical and safety properties with our in vivo drug metabolism and pharmacokinetic (DMPK) services to select the most robust drug formulations.

Learn More

Efficacy Testing

Explore how the novel HuGEMM™ and HuCELL™ platforms can assess the efficacy of your molecule and accelerate your immuno-oncology drug discovery programs.

Learn More

Laboratory Services

Employ cutting-edge multi-omics methods to obtain accurate and comprehensive data for optimal data-based decisions.

Learn More

Pharmacology & Bioanalytical Services

Leverage our suite of structural biology services including, recombinant protein expression and protein crystallography, and target validation services including RNAi.

Learn More


Find the most appropriate screen to accelerate your drug development: discover in vivo screens with MuScreen™ and in vitro cell line screening with OmniScreen™.

Learn More


Carry out safety pharmacology studies as standalone assessments or embedded within our overall toxicological profiling to assess cardiovascular, metabolic and renal/urinary systems.

Learn More

Our Company

Global CRO in California, USA offering preclinical and translational oncology platforms with high-quality in vivo, in vitro, and ex vivo models.

Learn More

Our Purpose

Learn more about the impact we make through our scientific talent, high-quality standards, and innovation.

Learn More

Our Responsibility

We build a sustainable future by supporting employee growth, fostering leadership, and exceeding customer needs. Our values focus on innovation, social responsibility, and community well-being.

Learn More

Meet Our Leadership Team

We build a sustainable future by fostering leadership, employee growth, and exceeding customer needs with innovation and social responsibility.

Learn More

Scientific Advisory Board

Our Scientific Advisory Board of experts shapes our strategy and ensures top scientific standards in research and development.

Learn More

News & Events

Stay updated with Crown Bioscience's latest news, achievements, and announcements. Check our schedule for upcoming events and plan your visit.

Learn More

Career Opportunities

Join us for a fast-paced career addressing life science needs with innovative technologies. Thrive in a respectful, growth-focused environment.

Learn More

Scientific Publications

Access our latest scientific research and peer-reviewed articles. Discover cutting-edge findings and insights driving innovation and excellence in bioscience.

Learn More


Discover valuable insights and curated materials to support your R&D efforts. Explore the latest trends, innovations, and expertly curated content in bioscience.

Learn More


Explore our blogs for the latest insights, research breakthroughs, and industry trends. Stay educated with expert perspectives and in-depth articles driving innovation in bioscience.

Learn More

  • Platforms
  • Target Solutions
  • Technologies
  • Service Types

2018 Technology Advances – Applying Next Generation Sequencing to Single Cell Analysis

cancer cell, next generation sequencing, single cell analysis, cell population heterogeneity

cancer cell, next generation sequencing, single cell analysis, cell population heterogeneityIt is an axiom in biology that expression of genotype determines phenotype. This means, for the large part, that the reason a cell does specialized functions is due to its mRNA and subsequent protein expression profile.

With continuing advances is nucleic acid sequencing technology we are moving into 2018 poised to understand a lot more about how individual cells behave in populations, and how heterogeneity develops in these populations.

Understanding Heterogeneity to Improve Cancer Outcomes

Why is this so important? Heterogeneity is a key feature of cancer and understanding its nature and origins in cancer may lead to better therapies.

Consider the following experiment. Take 1000 cancer cells and plate them at clonal density in semi-solid media, such as soft-agar. Incubate and wait for colonies to form. Let’s say that 50 colonies grow out; a clonogenic rate of 5% is pretty standard.

Now, harvest one of those colonies, disaggregate the cells and repeat the clonogenic experiment. What do you get? Again, a clonogenic rate of 5%. It seems that clonogenicity isn’t something that you can enrich for, this specialized trait is a cellular “state of mind”.

Metastasis as a Clonogenic Process

Cancer metastasis is the process by which cancer cells disseminate through the bloodstream or lymphatics and give rise to secondary tumor growths in organs distant from the primary cancer site. Metastasis is also the life threatening feature of cancer. It isn’t too much of a stretch to think of the seeding of metastases as a clonogenic process, knowing that cancer metastases themselves are clonal (1,2).

In 1976 Dr. Isaiah “Josh” Fidler generated the B16-F1/B16-F10 cell lines; B16-F10 being generated through repeated selection of cells capable of giving rise to metastases from the B16-F1 parental cells. In this experiment it was found that B16-F10 gave rise to more experimental lung metastases than the B16-F1 cell line.

In contrast to our analogous in vitro experiment, apparently the metastatic phenotype indeed could be enriched for. In his experiment, Dr Fidler concluded that the metastatic phenotype to some degree “breeds true”.

Quantitative Differences in Metastasis Formation Explored

However, eight years later, in 1984, a crucial but often overlooked study was published in Science which proposes quite a different interpretation of Dr. Fidler’s work. This paper explored quantitative differences in metastasis formation between the B16-F1 and B16-F10 cell lines. The conclusions from the paper were two-fold:

  1. That the vast majority of cells in either population were non-metastatic. Metastatic competence was a rare trait.
  2. Potentially the more intriguing discovery was, using Luria-Delbruck fluctuation analysis, that the difference between the two B16 cell lines was in fact the rate at which cells competent for metastasis arose in the population.

In other words, the difference between B16-F1 and B16-F10 was not in the process of metastasis itself, but in the frequency at which cells competent for metastasis emerged.

This conclusion is not inconsistent with Dr. Fidler’s observations, that B16-F10 is “more metastatic”. It is in contrast however, with the interpretation of how the generation of metastatic variants happens. Metastatic competence as it turns out, like clonogenicity in semi solid medium, again appeared to be a cellular “state-of-mind”.

“Dynamic Heterogeneity” Describes the Fluidity in Cell Population Heterogeneity

Dr. Hill and colleagues used the term “Dynamic Heterogeneity” to capture the idea that the generation of (phenotypic) heterogeneity in a cell population is fluid. Like a chemical equilibrium, the “arrow” points both ways.

To truly understand the nature of heterogeneity in a population, we must be able to analyze the individual members of that population. So, I used this introduction to highlight an area in which we have made interesting technological advances, which will hopefully be extended in 2018 – single cell analysis.

To date single cell analysis has been dominated by flow cytometry. It is now routine for experiments to involve the analysis in excess of 18 different markers on individual cells as they whizz by lasers and photomultiplier tubes. However, when we are talking about understanding the generation of heterogeneity, 18 markers aren’t nearly enough.

Next Generation Sequencing to Advance Single Cell Analysis

Next Generation Sequencing technology is now being applied to single cell analysis and it is with this technology that we are starting to make some interesting discoveries, which can be built upon in 2018.

One feature of gene expression that is becoming evident in single cells is that it follows a log-normal distribution. This might not be intuitive, as most of us tend to think linearly and not logarithmically. However, this observation feels right because we observe the same type of distribution in a typical flow cytometry experiment. Recall a typical frequency histogram generated by a flow cytometer reveals a normal distribution, but on a Log scale. The fact that the two observations align is reassuring.

The second observation in single cells that researchers are uncovering is evidence for multiple distributions, within a presumed uniform population. In this example a population of cells was treated with LPS and then analyzed for gene expression patterns at the single cell level. The outcome revealed a bimodal distribution for some genes, although uniform gene induction for others.

Looking at hematopoiesis in Zebrafish, this report suggests that single cell gene expression during differentiation reveals a continuum. It doesn’t seem to be that differentiation is a series of discrete “stations” along a pathway.

Technological Advances Help in Biological Understanding

Advances in technology have allowed physicists to peer deeper into atoms, only to uncover the fact that matter is made up of a strange assortment of even stranger particles. Uncovering the nature of clonogenicity and a deeper understanding of Dynamic Heterogeneity in cancer, through the use of NGS based single cell analysis, will hopefully shed light on the mysterious inner workings of cells.


  1. Yamamoto et al. Determination of clonality of metastasis by cell-specific color-coded fluorescent-protein imaging. Cancer Res 200;63(22):7785-90.
  2. Van Etten and Dehm. Clonal origin and spread of metastatic prostate cancer. Endocr Relat Cancer 2016;23(4):R207-R217.

Related Posts